Navigation Links
Borderline blood pressure- possible health risk

It is best to keep blood pressure at normal (120/80 mmHg). Better still, there is a benefit in keeping blood pressure as low as possible.High blood pressure is generally defined as a reading above 140/90 mm Hg and, if untreated, it raises the risk of stroke and heart attack. It's becoming increasingly clear that these figures don't represent a clear cut-off point below which there's no health risk. Research is now focussing upon the high normal or borderline group, with blood pressure of less than 140/90 but more than 130/85.//

Generally research studies show that people who have high normal blood pressure have an increased risk of death from heart attack or stroke, compared to those with optimal - 120/80 or low blood pressure. An ongoing study reveals that borderline blood pressure also increases the risk of non-fatal cardiovascular events.

The researchers, Boston University, studied nearly men and women, dividing them into three groups on the basis of blood pressure: borderline and optimal, as defined above, and an in-between group defined as normal where blood pressure lay between 130 and 120 (top figure) and 70 and 80 (bottom figure). Over the 12 years following initial blood pressure measurement, rates of cardiovascular events were1.5 per cent, 2.2 per cent and 4.1 per cent for women depending on whether blood pressure was optimal, normal or borderline. The figures for men were: 5.1 per cent, 6 per cent and 10 per cent.


Page: 1

Related medicine news :

1. Infant receives first bloodless liver transplant
2. Spouses and other partners lower blood pressure says new research
3. H2O - a cure for low blood pressure
4. Uncontrolled blood pressure
5. Nitric oxide involved in high blood pressure
6. Recouping blood flow after a stroke
7. Way to monitor blood pressure
8. Drugs disrupt formation of blood vessels
9. Gene therapy - Aim to improve blood flow
10. New Drug ALT-711 decreases blood vessel stiffness
11. Aggressive blood pressure treatment needed
Post Your Comments:

(Date:11/25/2015)... ... November 25, 2015 , ... Lakeview Health, ... country to celebrate their sobriety and show through pictures what a positive difference ... photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, and Instagram ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 23rd 2015 Cozy Products, ... heating products business. Cozy Products explains what this means for business moving forward. , ... the Cozy Products business model: to sell personal heaters that reduce energy consumption, are ...
(Date:11/25/2015)... Livonia, MI (PRWEB) , ... November 25, 2015 , ... ... at Presence Resurrection Medical Center (RMC) in Chicago, IL, UV Angel is evaluating the ... the medical and surgical intensive care units (totaling 30 beds) from May 2014 through ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... found that regular bras were incredibly uncomfortable," said an inventor from Bronx, N.Y. ... , She developed the patent-pending RECOVERY BRA for added comfort and support. The ...
(Date:11/25/2015)... ... , ... Since its launch in 2012, the Regenestem brand ... therapies to patients with chronic degenerative medical conditions. Now, the U.S. Patent and ... , Organizations are required to hold a registered trademark in order to make ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  Thanks to a donor with a ... Medical Center,s Sister Diane Grassilli Center for Women,s Health ... San Francisco . ... forward with a gift of $617,320 that allowed the ... with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional (3-D) ...
(Date:11/24/2015)... , Nov. 24, 2015  Array BioPharma Inc. ... Chief Executive Officer, Ron Squarer , will ... in New York.  The public is welcome to ... the Array BioPharma website.Event:Piper Jaffray Annual Healthcare ConferencePresenter:  ... December 2, 2015Time:1:30 p.m. Eastern Time Webcast: ...
(Date:11/24/2015)... Nov. 24, 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" ... announced today that the first patient has been enrolled ... a treatment for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States ... Phase 1/2 clinical trial, ESSA intends to demonstrate the ...
Breaking Medicine Technology: